Lantern Pharma (LTRN) Corporate presentation summary

Artificial intelligence-driven drug discovery and development

• RADRⓇ AI platform accelerates oncology drug discovery, reducing early-stage development timelines by 70% and costs by 80%.

• Platform powers 12 lead drug programs, with over 100 issued and pending patents.

• AI modules predict patient response with over 88% accuracy, supporting targeted clinical trials and collaborations.

• Strategic collaborations with leading academic and biopharma partners enhance data-driven insights and accelerate development.

• PredictBBBTM and withZeta expand AI capabilities for blood-brain barrier prediction and rare cancer research.

Clinical pipeline and drug programs

• Ten disclosed drug programs, including LP-300 for NSCLC in never smokers and LP-184 for DDR-deficient solid tumors.

• LP-300 Phase 2 Harmonic™ trial shows 86% clinical benefit rate and durable responses in never smokers with NSCLC.

• LP-184 completed Phase 1a basket trial with favorable safety, antitumor activity, and plans for Phase 1b/2 trials in TNBC, NSCLC, bladder cancer, and glioblastoma.

• LP-284 in Phase 1 for B-cell non-Hodgkin's lymphomas, showing complete response in heavily pre-treated patients and synergy with rituximab.

• STAR-001 (LP-184 for CNS cancers) demonstrates significant tumor regression and survival benefits in preclinical models, with multiple FDA designations.

Market potential and regulatory designations

• LP-300 targets a $4B+ global market in NSCLC for never smokers; LP-184 addresses a $10B+ US market in DDR-deficient solid tumors.

• LP-284 targets a $3-4B global market in B-cell NHL.

• STAR-001 addresses a $5-6B US market in CNS cancers.

• Twelve FDA designations, including Fast Track and Orphan Drug, for LP-184 and LP-284 across multiple indications.